Critical illness neuromyopathy

Brent P. Goodman, Andrea Boon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It was not until the seminal work of Bolton and colleagues in 1984, that the clinical, electrodiagnostic, and pathological features of neuromuscular weakness associated with critical illness were described, and the term critical illness polyneuropathy (CIP) was introduced. Given that neuropathy and myopathy may often occur together in the same patient, the term critical illness neuromyopathy (CINM) may be the most appropriate clinical designation of acquired neuromuscular weakness in the critically ill patient. The evidence-based discussion provided in this chapter focuses on the reduction of CINM incidence and severity, including the following three topics: Reduction of CINM incidence utilizing intensive insulin therapy; Treatment of CINM using early physical and occupational therapy and sedation interruption; and Reduction of CINM incidence using electrical muscle stimulation. The topics are preceded by a clinical scenario that provides the foundation for a clinical question, and for each topic a subsequent critical appraisal of the literature.

Original languageEnglish (US)
Title of host publicationEvidence-Based Neurology
Subtitle of host publicationManagement of Neurological Disorders: Second Edition
PublisherWiley-Blackwell
Pages243-248
Number of pages6
ISBN (Electronic)9781119067344
ISBN (Print)9780470657782
DOIs
StatePublished - Dec 11 2015

Fingerprint

Critical Illness
Incidence
Polyneuropathies
Occupational Therapy
Muscular Diseases
Secondary Prevention
Electric Stimulation
Insulin
Muscles
Therapeutics

Keywords

  • Critical illness myopathy
  • Critical illness neuromyopathy
  • Critical illness polyneuropathy
  • Electrical muscle stimulation
  • Intensive insulin therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Goodman, B. P., & Boon, A. (2015). Critical illness neuromyopathy. In Evidence-Based Neurology: Management of Neurological Disorders: Second Edition (pp. 243-248). Wiley-Blackwell. https://doi.org/10.1002/9781119067344.ch23

Critical illness neuromyopathy. / Goodman, Brent P.; Boon, Andrea.

Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell, 2015. p. 243-248.

Research output: Chapter in Book/Report/Conference proceedingChapter

Goodman, BP & Boon, A 2015, Critical illness neuromyopathy. in Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell, pp. 243-248. https://doi.org/10.1002/9781119067344.ch23
Goodman BP, Boon A. Critical illness neuromyopathy. In Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell. 2015. p. 243-248 https://doi.org/10.1002/9781119067344.ch23
Goodman, Brent P. ; Boon, Andrea. / Critical illness neuromyopathy. Evidence-Based Neurology: Management of Neurological Disorders: Second Edition. Wiley-Blackwell, 2015. pp. 243-248
@inbook{2ab986f9e8214a399047e69e25666f63,
title = "Critical illness neuromyopathy",
abstract = "It was not until the seminal work of Bolton and colleagues in 1984, that the clinical, electrodiagnostic, and pathological features of neuromuscular weakness associated with critical illness were described, and the term critical illness polyneuropathy (CIP) was introduced. Given that neuropathy and myopathy may often occur together in the same patient, the term critical illness neuromyopathy (CINM) may be the most appropriate clinical designation of acquired neuromuscular weakness in the critically ill patient. The evidence-based discussion provided in this chapter focuses on the reduction of CINM incidence and severity, including the following three topics: Reduction of CINM incidence utilizing intensive insulin therapy; Treatment of CINM using early physical and occupational therapy and sedation interruption; and Reduction of CINM incidence using electrical muscle stimulation. The topics are preceded by a clinical scenario that provides the foundation for a clinical question, and for each topic a subsequent critical appraisal of the literature.",
keywords = "Critical illness myopathy, Critical illness neuromyopathy, Critical illness polyneuropathy, Electrical muscle stimulation, Intensive insulin therapy",
author = "Goodman, {Brent P.} and Andrea Boon",
year = "2015",
month = "12",
day = "11",
doi = "10.1002/9781119067344.ch23",
language = "English (US)",
isbn = "9780470657782",
pages = "243--248",
booktitle = "Evidence-Based Neurology",
publisher = "Wiley-Blackwell",
address = "United States",

}

TY - CHAP

T1 - Critical illness neuromyopathy

AU - Goodman, Brent P.

AU - Boon, Andrea

PY - 2015/12/11

Y1 - 2015/12/11

N2 - It was not until the seminal work of Bolton and colleagues in 1984, that the clinical, electrodiagnostic, and pathological features of neuromuscular weakness associated with critical illness were described, and the term critical illness polyneuropathy (CIP) was introduced. Given that neuropathy and myopathy may often occur together in the same patient, the term critical illness neuromyopathy (CINM) may be the most appropriate clinical designation of acquired neuromuscular weakness in the critically ill patient. The evidence-based discussion provided in this chapter focuses on the reduction of CINM incidence and severity, including the following three topics: Reduction of CINM incidence utilizing intensive insulin therapy; Treatment of CINM using early physical and occupational therapy and sedation interruption; and Reduction of CINM incidence using electrical muscle stimulation. The topics are preceded by a clinical scenario that provides the foundation for a clinical question, and for each topic a subsequent critical appraisal of the literature.

AB - It was not until the seminal work of Bolton and colleagues in 1984, that the clinical, electrodiagnostic, and pathological features of neuromuscular weakness associated with critical illness were described, and the term critical illness polyneuropathy (CIP) was introduced. Given that neuropathy and myopathy may often occur together in the same patient, the term critical illness neuromyopathy (CINM) may be the most appropriate clinical designation of acquired neuromuscular weakness in the critically ill patient. The evidence-based discussion provided in this chapter focuses on the reduction of CINM incidence and severity, including the following three topics: Reduction of CINM incidence utilizing intensive insulin therapy; Treatment of CINM using early physical and occupational therapy and sedation interruption; and Reduction of CINM incidence using electrical muscle stimulation. The topics are preceded by a clinical scenario that provides the foundation for a clinical question, and for each topic a subsequent critical appraisal of the literature.

KW - Critical illness myopathy

KW - Critical illness neuromyopathy

KW - Critical illness polyneuropathy

KW - Electrical muscle stimulation

KW - Intensive insulin therapy

UR - http://www.scopus.com/inward/record.url?scp=85017992014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017992014&partnerID=8YFLogxK

U2 - 10.1002/9781119067344.ch23

DO - 10.1002/9781119067344.ch23

M3 - Chapter

SN - 9780470657782

SP - 243

EP - 248

BT - Evidence-Based Neurology

PB - Wiley-Blackwell

ER -